Organic compounds
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT 2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D 1 and D 2 receptor signaling system, and/or the μ-opioid receptor.
1. A compound according to Formula I:
wherein:
X is NH;
L is O;
Z is —O— or —C(O)—;
in free form, salt form, or pharmaceutically acceptable salt form.
2. The compound according to claim 1 , wherein Z is —C(═O)—.
3. The compound according to claim 1 , wherein Z is O—.
4. The compound according to claim 3 in free form.
5. The compound according to claim 4 in solid form.
6. The compound according to claim 3 in pharmaceutically acceptable salt form.
7. The compound according to claim 6 , wherein the compound is in acid addition salt form with an acid selected from glutamic acid, tartaric acid, malic acid or ascorbic acid.
8. A pharmaceutical composition comprising the compound according to claim 1 in admixture with a pharmaceutically acceptable diluent or carrier.
9. The composition according to claim 8 , wherein the pharmaceutically acceptable diluent or carrier comprises a polymeric matrix.
10. The composition according to claim 9 , wherein the polymeric matrix comprises a biodegradable poly(d,l-lactide-co-glycolide) microsphere.
11. A pharmaceutical composition comprising the compound according to claim 3 in admixture with a pharmaceutically acceptable diluent or carrier.
12. A pharmaceutical composition comprising the compound according to claim 4 in admixture with a pharmaceutically acceptable diluent or carrier.
13. The composition according to claim 12 , wherein the pharmaceutically acceptable diluent or carrier comprises a polymeric matrix.
14. The composition according to claim 13 , wherein the polymeric matrix comprises a biodegradable poly(d,l-lactide-co-glycolide) microsphere.
15. A pharmaceutical composition comprising the compound according to claim 7 in admixture with a pharmaceutically acceptable diluent or carrier.
16. The composition according to claim 15 , wherein the pharmaceutically acceptable diluent or carrier comprises a polymeric matrix.
17. The composition according to claim 16 , wherein the polymeric matrix comprises a biodegradable poly(d,l-lactide-co-glycolide) microsphere.